United Therapeutics Cleared to Proceed with Phase 1 in Pulmonary Arterial Hypertension

 If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH)

This investigational therapy combines two potent prostacyclin analogues, treprostinil and iloprost, and is delivered as an inhalation spray via a soft mist inhaler for pro re nata (PRN) use

https://www.businesswire.com/news/home/20261028830210/en/United-Therapeutics-Announces-FDA-Clearance-to-Proceed-with-Clinical-Trial-for-Treprostinil-Iloprost-SMI-in-Pulmonary-Arterial-Hypertension